VCEL Vericel Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCEL

Price (delayed)

$47.83

Market cap

$2.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$2.31B

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured ...

Highlights
The net income has soared by 81% YoY and by 69% QoQ
The EPS has soared by 80% YoY and by 68% from the previous quarter
The debt has soared by 85% YoY and by 3.6% QoQ
The quick ratio has declined by 13% since the previous quarter and by 8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://vcel.com
Peers: RPRX NEOG NURO

Key stats

What are the main financial stats of VCEL
Market
Shares outstanding
48.29M
Market cap
$2.31B
Enterprise value
$2.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.1
Price to sales (P/S)
11.52
EV/EBIT
N/A
EV/EBITDA
258.66
EV/Sales
11.7
Earnings
Revenue
$197.52M
EBIT
-$1.77M
EBITDA
$8.93M
Free cash flow
$15.3M
Per share
EPS
-$0.07
Free cash flow per share
$0.32
Book value per share
$4.73
Revenue per share
$4.15
TBVPS
$7.29
Balance sheet
Total assets
$353.66M
Total liabilities
$127.71M
Debt
$88.04M
Equity
$225.95M
Working capital
$159.88M
Liquidity
Debt to equity
0.39
Current ratio
4.49
Quick ratio
4.06
Net debt/EBITDA
0.13
Margins
EBITDA margin
4.5%
Gross margin
68.6%
Net margin
-1.6%
Operating margin
-3.3%
Efficiency
Return on assets
-1%
Return on equity
-1.5%
Return on invested capital
-0.7%
Return on capital employed
-0.6%
Return on sales
-0.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCEL stock price

How has the Vericel stock price performed over time
Intraday
-0.1%
1 week
3.87%
1 month
-6.82%
1 year
48.91%
YTD
34.32%
QTD
-8.05%

Financial performance

How have Vericel's revenue and profit performed over time
Revenue
$197.52M
Gross profit
$135.58M
Operating income
-$6.46M
Net income
-$3.18M
Gross margin
68.6%
Net margin
-1.6%
The net margin has soared by 84% YoY and by 71% QoQ
The net income has soared by 81% YoY and by 69% QoQ
Vericel's operating margin has soared by 68% YoY and by 54% from the previous quarter
Vericel's operating income has surged by 62% YoY and by 51% QoQ

Growth

What is Vericel's growth rate over time

Valuation

What is Vericel stock price valuation
VCEL P/E details
P/E
N/A
P/B
10.1
P/S
11.52
EV/EBIT
N/A
EV/EBITDA
258.66
EV/Sales
11.7
The EPS has soared by 80% YoY and by 68% from the previous quarter
VCEL's price to book (P/B) is 28% higher than its last 4 quarters average of 7.9 and 12% higher than its 5-year quarterly average of 9.0
The equity rose by 18% year-on-year and by 11% since the previous quarter
VCEL's price to sales (P/S) is 29% higher than its last 4 quarters average of 8.9 and 23% higher than its 5-year quarterly average of 9.4
The revenue has grown by 20% YoY and by 7% from the previous quarter

Efficiency

How efficient is Vericel business performance
The ROIC has soared by 91% year-on-year and by 81% since the previous quarter
The ROS has soared by 91% YoY and by 82% from the previous quarter
Vericel's return on assets has surged by 85% YoY and by 71% QoQ
VCEL's ROE has soared by 84% YoY and by 71% from the previous quarter

Dividends

What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCEL.

Financial health

How did Vericel financials performed over time
The total assets is 177% higher than the total liabilities
Vericel's total liabilities has soared by 58% YoY and by 12% from the previous quarter
The total assets has increased by 30% YoY and by 11% QoQ
The debt is 61% lower than the equity
The debt has soared by 85% YoY and by 3.6% QoQ
Vericel's debt to equity has soared by 56% YoY but it has decreased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.